AbbVie deal may conclude a tumultuous 4 years for Botox-maker Allergan
June 26, 2019 at 06:00 AM EDT
AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.
